Why the study?
Do commercial VWF:CB assays accurately discriminate between types 1 and 2 von Willebrand disease compared to in-house reference assays?
Do commercial VWF:CB assays accurately discriminate between types 1 and 2 von Willebrand disease compared to in-house reference assays?
Commercial VWF:CB assays exhibit variability in discriminating VWD types and require further standardization before widespread diagnostic use.
This is the authors' abstract. We don't add key points for this paper.
This study reports on the evaluation of seven commercial von Willebrand factor (VWF) collagen binding (VWF:CB) assays to potentially assist the discrimination of types 1 and 2 von Willebrand disease (VWD). Samples from 25 patients with type 1 VWD, of varying severity, were co-tested with 16 samples from patients with types 2A or 2B VWD, plus various control samples, using each commercial VWF:CB assay assessed against our standard (reference) in-house VWF:CB assay, as well as our in-house VWF antigen (VWF:Ag) and ristocetin cofactor (VWF:RCo) assays. Commercial VWF:CB assays varied in their ability to discriminate types 1 and 2A/2B VWD. The optimal VWF:CB/VWF:Ag ratio at which optimal discrimination occurred also differed between assays, with some improvements observed with some (but not all) assays following a harmonisation process that aimed to correct for different calibrator effects. Assay variability also compromised assay utility in some test occasions. Future standardisation and improvements in some commercial VWF:CB assays are needed before the VWF:CB assay can be more fully and globally utilised for discrimination of VWD types in diagnostic laboratories.
Answers are grounded in this paper and cite their sources.
Assay variability may limit reliable VWD subtyping; leaves open need for standardization before clinical use.
No takes yet. Share an insight, caveat, or question.
Emmanuel J. Favaloro (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: